Source: Annual Congress 2006 - Biology and prognostic factors
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
M. Petrovic, I. Tomic, I. Jevtovic, Z. Lazic, I. Cekerevac, S. Mojsilovic, L. Novkovic (Kragujevac, Belgrade, Serbia And Montenegro). The predictive value of neuroendocrine markers for response to chemotherapy and survival in patients with non-small cell lung. Eur Respir J 2006; 28: Suppl. 50, 2287

Member's Comments

No comment yet.

Related content which might interest you: Effects of prognostic factors on survival of the patients of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 326s Year: 2005 Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 Adjuvant chemotherapy in completely resected non-small cell lung cancer: Frequency of biological markers of predictive value Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010 ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer Year: 2009 Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy Source: Eur Respir Rev 2013; 22: 565-576 Year: 2013 Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002 The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005 Prognostic factors affecting survival in advanced non-small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 75s Year: 2004 TTF-1 for prediction of response to chemotherapy in patients with locally advanced or metastatic small cell lung cancer (SCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 The impact of neuroendocrine differentiation in the prognosis of non-small cell lung cancer Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Effects of pretreatment prognostic factors and treatment on survival in advanced nonsmall cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 431s Year: 2003 Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011 A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 FDG-PET SUVmax is an independent prognostic indicator in patients with non-small cell lung cancer Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 Does long treatment delay affect survival in metastatic non-small cell lung cancer Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Assessing the relevance of biological prognostic indices in predicting survival in non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy? Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies Year: 2007 Prognostic value of neutrophil to lymphocyte ratio in patients with advanced non-small cell lung cancer Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021 Tumour metabolic-flow difference as a potential predictor of survival in non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Staging of lung cancer Year: 2010